Prof.DavidLui Hong Kong, China

Prof.DavidLui
Prof David Lui obtained his MBBS degree with Honours from the University of Hong Kong and completed his specialty training in Endocrinology, Diabetes, and Metabolism at Queen Mary Hospital. He joined the Department of Medicine at the University of Hong Kong as a Clinical Assistant Professor in March 2021. His research interests include bone and muscle health in diabetes, dyslipidaemia in diabetes, and endocrine epidemiology and pharmacoepidemiology. Supported by the Health and Medical Research Fund, he is leading a randomized controlled trial on the effects of statins on bone health in postmenopausal women with type 2 diabetes, studying the epidemiology of fractures in type 2 diabetes within Hong Kong, and examining the long-term impacts of COVID-19 on metabolic disorders. Prof Lui has established cohorts to evaluate bone and muscle health in individuals with and without diabetes and has contributed to the development of the 2024 OSHK Guideline for the Clinical Management of Postmenopausal Osteoporosis in Hong Kong, particularly the section on ‘Diabetes and Osteoporosis’. Additionally, he was a visiting fellow at the University of New South Wales, Sydney, during 2024/25, where he studied high-density lipoprotein function in type 2 diabetes under the mentorship of Professor Kerry Rye. He has authored over 110 peer-reviewed articles in international journals, including Nature Reviews Endocrinology, Diabetes Care, EClinicalMedicine, JAMA Surgery, and JAMA Network Open. Two of his publications have been listed among the Highly Cited Papers in the Essential Science Indicators (ESI). In recognition of his research contributions, he has received numerous awards, including the Distinguished Research Paper Award for Young Investigators from the Hong Kong College of Physicians (2021, 2022, and 2023) and the Rising Star Award at the International Congress of Diabetes and Metabolism (2021). He currently serves on the Editorial Boards of The Journal of Clinical Endocrinology and Metabolism and Endocrine Practice. He is an Executive Committee member of the Asia-Pacific Consortium on Osteoporosis (APCO) and the Communication Workgroup Co-lead of the Asia-Pacific Cardio-Metabolic Consortium (APCMC). He is also the Secretary of the Diabetes Division of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (HKSEMR).

21 MARCH

Time Session
08:30
10:00
[Symposium] Osteoporosis
Osteoporosis and Bone Health
  • New Concept in Osteoporosis Management
    Daisuke InoueJapan Speaker New Concept in Osteoporosis Management- Japnaese Perspectives Operational definition of osteoporosis by WHO is currently "a BMD value -2.5SD or more below the young adult mean", which has been used worldwide for twenty years. WHO has recently initiated a process to revisit this definition as it is not sensitive enough to identify individuals at high risk of fracture, leading to unsatisfactory treatment of patients. Importantly, a history of fracture, particularly within the past two years (termed imminent fracture risk) has been shown to significantly contribute to the risk of subsequent fractures. Regarding a surrogate for evaluating the clinical efficacy of anti-osteoporotic drugs, a proposal from the FNIH-ASBMR-SABRE project has been submitted to the Food and Drug Administration (FDA). This proposal suggests that treatment-related increases in total hip BMD (TH-BMD) at two years could serve as a surrogate endpoint for fracture risk reduction in clinical trials. This is primarily based on the negative correlation observed between increases in total hip BMD and decreases in the incidence of hip fracture in various clinical trials of anti-osteoporotic drugs demonstrated by a meta-regression analysis. The significant role of BMD as a surrogate, along with availability of bone anabolic agents that can greatly increase BMD for a short period of time, has led to the concept of "Goal-directed treatment" of osteoporosis. Accordingly, "anabolic first" sequential therapy is recommended for individuals at high risk of fractures. In Japan, new Guidelines for Prevention and Treatment of Osteoporosis were issued on August 1, 2025. Recent trends in osteoporosis management, as described above, will be discussed in the context of these Japanese guidelines.
  • Bone Fragility in Diabetes
    David LuiHong Kong, China Speaker Bone Fragility in Diabetes
  • Metabolic Bone Disorder in Thalassemia
    Wen-Pin YangTaiwan Speaker Metabolic Bone Disorder in Thalassemia
201AF